Tectonic Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$702K Sell
1,126
-6
-0.5% -$4.08K 0.03% 219
2026
Q1
$875K Sell
1,132
-11
-1% -$8.42K 0.05% 175
2025
Q4
$882K Sell
1,143
-63
-5% -$42.8K 0.05% 185
2025
Q3
$678K Sell
1,206
-51
-4% -$28.8K 0.04% 211
2025
Q2
$660K Buy
1,257
+358
+40% +$200K 0.04% 209
2025
Q1
$570K Buy
899
+69
+8% +$47.5K 0.04% 223
2024
Q4
$591K Buy
830
+118
+17% +$99K 0.04% 214
2024
Q3
$748K Sell
712
-72
-9% -$80.1K 0.05% 192
2024
Q2
$824K Buy
784
+33
+4% +$32K 0.06% 181
2024
Q1
$723K Sell
751
-32
-4% -$30.4K 0.06% 187
2023
Q4
$688K Buy
783
+14
+2% +$11.5K 0.06% 177
2023
Q3
$633K Buy
769
+35
+5% +$27.5K 0.06% 169
2023
Q2
$527K Buy
734
+46
+7% +$35.5K 0.06% 188
2023
Q1
$565K Buy
688
+158
+30% +$119K 0.08% 170
2022
Q4
$382K Sell
530
-9
-2% -$6.64K 0.06% 193
2022
Q3
$371K Buy
539
+41
+8% +$25.8K 0.07% 149
2022
Q2
$294K Buy
498
+41
+9% +$26.7K 0.05% 159
2022
Q1
$319K Buy
457
+69
+18% +$43.7K 0.05% 156
2021
Q4
$245K Buy
+388
New +$239K 0.04% 172
2021
Q1
Sell
-1,133
Closed -$547K 205
2020
Q4
$547K Buy
+1,133
New +$612K 0.15% 93

Other funds holding REGN

Tectonic Advisors's REGN Position: Q2 2026 in Review

Tectonic Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.53% in Q2 2026, selling an estimated $4.08K and leaving 1,126 shares worth $702K. The position accounts for 0.03% of the portfolio, ranked #219.

Tectonic Advisors first reported a position in REGN in Q4 2020 and has held it in 20 quarters since. The position peaked at $882K in Q4 2025. 208 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Tectonic Advisors held 1,126 shares of Regeneron Pharmaceuticals worth $702K as of Q2 2026.
  • Tectonic Advisors sold 6 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.08K.
  • Regeneron Pharmaceuticals made up 0.03% of Tectonic Advisors's portfolio in Q2 2026, its #219 holding.
  • Tectonic Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • Tectonic Advisors's Regeneron Pharmaceuticals position peaked at $882K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Tectonic Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.